MARC N. CASPER - 05 Mar 2026 Form 4 Insider Report for THERMO FISHER SCIENTIFIC INC. (TMO)

Role
Chairman & CEO, Director
Signature
/s/ Melodie T. Morin, Attorney-in-Fact for Marc N. Casper
Issuer symbol
TMO
Transactions as of
05 Mar 2026
Net transactions value
-$2,059,261
Form type
4
Filing time
09 Mar 2026, 16:39:01 UTC
Previous filing
05 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
CASPER MARC N Chairman & CEO, Director 168 THIRD AVENUE, WALTHAM /s/ Melodie T. Morin, Attorney-in-Fact for Marc N. Casper 09 Mar 2026 0001216055

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMO Common Stock Options Exercise +4,000 +3.2% $309.63* 127,925 05 Mar 2026 Direct
transaction TMO Common Stock Sale $10,073 -20 -0.02% $503.66 127,905 05 Mar 2026 Direct F1
transaction TMO Common Stock Sale $30,346 -60 -0.05% $505.76 127,845 05 Mar 2026 Direct F1, F2
transaction TMO Common Stock Sale $29,437 -58 -0.05% $507.54 127,787 05 Mar 2026 Direct F1, F3
transaction TMO Common Stock Sale $50,456 -99 -0.08% $509.66 127,688 05 Mar 2026 Direct F1, F4
transaction TMO Common Stock Sale $109,521 -214 -0.17% $511.78 127,474 05 Mar 2026 Direct F1, F5
transaction TMO Common Stock Sale $210,732 -411 -0.32% $512.73 127,063 05 Mar 2026 Direct F1, F6
transaction TMO Common Stock Sale $582,033 -1,133 -0.89% $513.71 125,930 05 Mar 2026 Direct F1, F7
transaction TMO Common Stock Sale $293,385 -570 -0.45% $514.71 125,360 05 Mar 2026 Direct F1, F8
transaction TMO Common Stock Sale $179,443 -348 -0.28% $515.64 125,012 05 Mar 2026 Direct F1, F9
transaction TMO Common Stock Sale $103,863 -201 -0.16% $516.73 124,811 05 Mar 2026 Direct F1, F10
transaction TMO Common Stock Sale $54,890 -106 -0.08% $517.83 124,705 05 Mar 2026 Direct F1, F11
transaction TMO Common Stock Sale $267,871 -516 -0.41% $519.13 124,189 05 Mar 2026 Direct F1, F12
transaction TMO Common Stock Sale $137,211 -264 -0.21% $519.74 123,925 05 Mar 2026 Direct F1, F13
holding TMO Common Stock 11,300 05 Mar 2026 By Alison Casper 2020 Irrevocable Trust F14
holding TMO Common Stock 14,608 05 Mar 2026 By Floral Park Associates, Inc.
holding TMO Common Stock 5,000 05 Mar 2026 By MNC 2020 Irrevocable Trust F15

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TMO Stock Option (Right to Buy) Options Exercise -4,000 -9% $0.000000* 40,550 05 Mar 2026 Common Stock 4,000 $309.63 Direct F16
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2025.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $505.36 to $506.16, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $507.40 to $508.12, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $509.63 to $509.76, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $511.21 to $512.18, inclusive.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $512.23 to $513.22, inclusive.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $513.27 to $514.24, inclusive.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $514.28 to $515.24, inclusive.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $515.30 to $516.00, inclusive.
F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $516.47 to $517.07, inclusive.
F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $517.60 to $518.16, inclusive.
F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $518.62 to $519.57, inclusive.
F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $519.62 to $519.91, inclusive.
F14 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein.
F15 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein.
F16 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024.